Elicio Therapeutics, a Cambridge, MA-based immuno-oncology company, engineering therapies for cancer killing immune responses, raised $30m in funding.
The backers were not disclosed.
The company intends to use the funds to advance its therapies.
Led by Robert Connelly, CEO, and Executive Chairman Julian Adams, Ph.D., Elicio is developing precision vaccines, immuno stimulators and cellular therapies based on the work of Darrell Irvine, Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
The company is engineering potent cancer vaccines and immunotherapies for an array of aggressive solid and hematologic cancers.
Elicio’s Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune defenses, with the aim to achieve durable cures.
The company’s lead vaccines targeting pancreatic, colorectal and head and neck cancers will enter initial patient studies in the first half of 2020. These programs are followed by a broad preclinical pipeline of vaccines, adjuvants, cellular therapy vaccines and immuno stimulatory therapeutics.